However, other researchers found that FOXO1 promoted resistance of non-Hodgkin lymphomas to anti-CD20-based therapy and played a tumor-promoting role in FLT3-ITD+ AML through a complex mechanism, respectively [17,18]. Here, FOXO1 is linked to neoplasm.